Volume and Location Analysis of Intracerebral Hemorrhage for the Appropriate Use of Andexanet Alfa [PDF]
Neurologia Medico-ChirurgicaAndexanet alfa was approved as a reversal agent for Factor Xa inhibitors in patients with uncontrolled or life-threatening bleeding, such as intracerebral hemorrhage. However, its use in cases of small hemorrhages remains controversial.
Takeru UMEMURA +13 more
doaj +2 more sources
Trends and variation in the use of andexanet alfa for the reversal of direct oral anticoagulants in NHS trusts in England [PDF]
British Journal of Clinical Pharmacology, Volume 92, Issue 6, Page 1607-1613, June 2026.Abstract Aims Andexanet alfa was recommended by the National Institute for Health and Clinical Excellence (NICE) as an option in the management of life‐threatening gastrointestinal bleeding in patients taking apixaban or rivaroxaban in May 2021. A recent UK‐wide survey of local hospital protocols for the use of andexanet alfa suggested that practice ...
Louis Fisher +11 more
wiley +2 more sources
Use of andexanet alfa: A British Society for Haematology position statement [PDF]
Br J HaematolBritish Journal of Haematology, Volume 208, Issue 6, Page 1939-1941, June 2026.
Richard J. Buka +10 more
wiley +2 more sources
Procoagulant off-target effect of the direct oral anticoagulant reversal agent Andexanet alfa [PDF]
Blood Vessels, Thrombosis & Hemostasis: Patients with hemorrhage after treatment with direct oral anticoagulants (DOACs) are saved from hematoma expansion by administration of Andexanet alfa, a modified factor Xa analog.
Ischa M. S. Hoornstra +9 more
doaj +2 more sources
Real-world andexanet alfa utilization and the association between delay in administration due to hospital transfer and all-cause inpatient mortality [PDF]
Research and Practice in Thrombosis and HaemostasisBackground: Evaluations of andexanet alfa for the reversal of factor Xa inhibitor-associated bleeding have been small, with cohorts drawn from single/limited sites.
Huiqiao Fan +2 more
doaj +2 more sources
Andexanet alfa: trials just leave us with more questions [PDF]
Research and Practice in Thrombosis and HaemostasisAndexanet Alfa in Acute Intracranial Hemorrhage in Patients Receiving an Oral Factor Xa Inhibitor (ANNEXA-I), the first ever randomized controlled trial of a reversal agent for direct oral anticoagulants, was published in 2024.
Richard J. Buka
doaj +2 more sources
Andexanet alfa for the reversal of the low-molecular-weight heparin enoxaparin [PDF]
Research and Practice in Thrombosis and HaemostasisBackground: Andexanet alfa (andexanet) is the only approved reversal agent for patients with acute major bleeding during apixaban or rivaroxaban treatment. Its mechanism suggests it may also reverse the effects of low-molecular-weight heparin.
Thijs F. van Haaps +11 more
doaj +2 more sources
First use of andexanet alfa in the management of massive delayed hemothorax [PDF]
Turkish Journal of Emergency MedicineIn emergency medicine practice, massive hemothorax represents a life-threatening condition in patients with comorbidities. We present the case of a 75-year-old female patient with a massive delayed hemothorax, which developed following a chest injury ...
Miroslaw Kozlowski +4 more
doaj +2 more sources
Fatal drug reaction to andexanet alfa: a case report [PDF]
eJHaemAndexanet alfa is a recombinant, modified factor Xa (FXa) molecule that is used for the reversal of the anticoagulant effect of oral anti‐FXa anticoagulants in patients with major haemorrhage.
Richard J. Buka +2 more
doaj +2 more sources
Position statement of the Polish Society of Gastroenterology on the use of andexanet alfa in patients with gastrointestinal bleeding taking factor Xa inhibitors [PDF]
Gastroenterology ReviewIn Poland, there has been a steady increase in the number of patients receiving factor Xa (FXa) inhibitors as part of anticoagulant therapy. Despite their high therapeutic efficacy and the lack of a need for dose monitoring, these agents are responsible ...
Krystian Adrych +4 more
doaj +2 more sources